Get started
Redhill Biopharma Ltd.Redhill Biopharma Ltd.Redhill Biopharma Ltd.

Redhill Biopharma Ltd.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

RDHL trade ideas

RDHL | Good Entry Point | LONGRedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
NASDAQ:RDHLLong
by DivergenceSeeker
2
RDHL, enters Downtrend as Momentum drops below 0 level 09/29/20This indicator may be signaling that RDHL's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. Tickeron A.I.dvisor backtested 85 similar cases where RDHL's Momentum Indicator fell below the 0 level, and 71 of them led to a successful outcome. Odds of Success: 84%. Current price $10.32 is above $8.25 the highest resistance line found by Tickeron A.I. Throughout the month of 08/27/20 - 09/29/20, the price experienced a +34% Uptrend, while the week of 09/22/20 - 09/29/20 shows a -2% Downtrend. Bearish Trend Analysis The Stochastic Indicator may be shifting from an upward trend to a downward trend. In 38 of 50 cases where RDHL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%. The Momentum Indicator moved below the 0 level on September 29, 2020. You may want to consider selling the stock, shorting the stock, or exploring put options on RDHL as a result. Tickeron A.I. detected that in 71 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%. The Moving Average Convergence Divergence Histogram (MACD) for RDHL turned negative on September 25, 2020. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 37 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 74%. Following a 3-day decline, the stock is projected to fall further. Considering past instances where Apple declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
NASDAQ:RDHLShort
by AlTorress
$RDHL - Next level within closing above 7 onlyThe first two patients have been treated with opaganib at a leading hospital in Israel. At the time of treatment initiation, both patients suffered from moderate to severe acute respiratory symptoms related to SARS-CoV-2 infection, required supplemental oxygenation and were hypoxic despite being treated with maximum flow of oxygen with cannulas. Preliminary findings from both patients demonstrated clinical improvement within days post treatment-initiation with opaganib. To date, both patients have shown decreased supplemental oxygen requirements and decreased C-reactive protein (CRP) levels, an important inflammatory biomarker correlated with lung lesions which could reflect disease severity2. Both patients have also shown an increase in lymphocyte levels, a sign of improvement from virus-induced lymphopenia. One of the patients was being treated in the intensive care unit (ICU), was considered for intubation, and was released from the ICU within days of treatment initiation with opaganib. Opaganib was administered to the hospitalized patients in addition to standard-of-care, which included hydroxychloroquine (HCQ) as background therapy. Opaganib was well tolerated at the doses administered and no opaganib-related treatment emergent adverse events have been reported to date. In addition, approximately 160 patients are planned to be treated in three major hospitals in northern Italy under an expanded access program approved by the Italian National Institute for Infectious Diseases, allowing compassionate use of opaganib, for patients with confirmed SARS-CoV-2 infection with life-threatening manifestations. Not for a suggestion!
NASDAQ:RDHL
by Samuel12_1980
RedHill Biopharma Ltd. on breakout watchRedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.
NASDAQ:RDHL
by DEXWireNews
1
$RDHL - " Talicia® available through pharmacies nationwide."TEL-AVIV, Israel and RALEIGH, N.C., March 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Express Scripts has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)1 to its National Preferred Formulary as a preferred brand. RedHill recently launched Talicia® in the U.S., making Talicia® available through pharmacies nationwide. “The addition of Talicia® to Express Scripts’ National Preferred Formulary reflects the urgent need for new therapies addressing the high resistance rates of H. pylori to standard-of-care antibiotics, as highlighted by the FDA and the World Health Organization in recent years. The high resistance rates have led to the declining efficacy of current standard-of-care clarithromycin-based therapies. Talicia® has a good safety and efficacy profile that is not compromised by clarithromycin resistance,” said Rick Scruggs, Chief Commercial Officer of RedHill. “H. pylori infection is a Class I carcinogen and the strongest known risk factor for development of peptic ulcer disease and gastric cancer. The addition of Talicia® to the National Preferred Formulary will allow millions of patients unrestricted access to this important new treatment. We expect to secure additional formulary coverage in the coming weeks and months to allow more patients to benefit from Talicia®.” Talicia® is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to clarithromycin-based standard-of-care therapies. The high rates of H. pylori resistance to clarithromycin have led to significant rates of treatment failure with clarithromycin-based standard-of-care therapy and are a strong public health concern. Minimal to zero resistance to rifabutin, a key component of Talicia®, was detected in RedHill’s pivotal Phase 3 study. Let break that triangle and pass 4.82-5$
NASDAQ:RDHLLong
by Samuel12_1980
$RDHL - Aemcolo® and Talicia® in Q4/2019 and Q1/2020• U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults • Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to commercialize Aemcolo® in the U.S. for travelers’ diarrhea • Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in Q4/2019 and Q1/2020, respectively • Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo Pharmaceuticals. Technically, as long it above 6.1, target it 6.7 and 7 . Good-luck Not for a suggestion.
NASDAQ:RDHL
by Samuel12_1980
$RDHL - FDA Approved today RHB-105RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Š Talicia® is the first and only FDA approved rifabutin-based H. pylori therapy and is designed to address the high and growing bacterial resistance and diminished efficacy of clarithromycin-based standard-of-care therapy Š H. pylori affects approximately 35% of U.S. adult population; it is classified as a Group I carcinogen and is the strongest risk factor for the development of peptic ulcer disease, gastritis and non-cardia gastric cancer Š Talicia® is eligible for 8 years of U.S. market exclusivity under QIDP designation, in addition to patent protection extending until 2034 Š Debt-free balance sheet with approximately $59 million in cash and short-term investments following a recent strategic investment by Cosmo Pharmaceuticals Š RedHill will host Investor and Analyst day and live webcast on November 22, 2019 to present its planned commercial launch of Talicia® and Aemcolo® Technically - 2 resistance at 8.54 and 9.57 (Above is the moon)
NASDAQ:RDHL
by Samuel12_1980
$RDHLVery critical month (November 2): Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA action date of November 2, 2019 • Preparations ongoing for the potential U.S. commercial launch of Talicia® in Q4/2019, subject to FDA approval, with RedHill’s established sales force, led by the Company’s experienced commercial management team • FDA meetings planned to take place in H2/2019 to discuss the path to potential approval of RHB-104 for Crohn’s disease • Initiation of pivotal Phase 3 study activities with RHB-204 for first-line treatment of pulmonary nontuberculous mycobacteria (NTM) infections expected in Q4/2019 • Debt-free balance sheet with $34.9 million cash balance as of June 30, 2019 All of the above at your discretion, your accepted trading rules, trading strategies and your preferred trading management. This is not a recommendation to buy or sell.
NASDAQ:RDHL
by Samuel12_1980